Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Eyepoint Inc (EYPT)

Eyepoint Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EyePoint: Q2 Earnings Snapshot AP - Wed Aug 5, 6:33AM CDT

EyePoint: Q2 Earnings Snapshot

EYPT : 12.83 (+4.73%)
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments GlobeNewswire - Wed Aug 5, 6:00AM CDT

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 ––...

EYPT : 12.83 (+4.73%)
EyePoint's Trial Data Window Opens This Quarter: What If the Readout Doesn't Deliver? Barchart - Tue Aug 4, 4:13PM CDT

Barchart Research What to Expect from EYPT Earnings EYPT Generated August 4, 2026 Current Price $11.70 EPS Estimate $$-0.92 Consensus Rating Strong Buy Average Move 4.69% EyePoint's Trial Data Window Opens...

EYPT : 12.83 (+4.73%)
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) GlobeNewswire - Thu Jul 30, 6:00AM CDT

– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– ...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Thu Jul 16, 6:00AM CDT

WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer GlobeNewswire - Mon Jul 13, 6:00AM CDT

WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Tue Jun 16, 6:00AM CDT

WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
MarketBeat.com
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears MarketBeat - Tue May 26, 11:04AM CDT

Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901,...

EYPT : 12.83 (+4.73%)
EyePoint Announces Participation at Upcoming Investor Conferences GlobeNewswire - Tue May 19, 6:00AM CDT

WATERTOWN, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Mon May 18, 6:00AM CDT

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious...

EYPT : 12.83 (+4.73%)

Barchart Exclusives

The Data Center Boom Is Powering Utility Earnings. Here Is My Favorite Way to Play the Trend. Barchart - Thu Aug 6, 6:30PM CDT
Utility companies are increasingly benefiting from the AI data center boom, and here is my favorite way to gain exposure to this investment theme. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.